Allena Pharmaceuticals, Inc. (ALNA) financial statements (2020 and earlier)

Company profile

Business Address ONE NEWTON EXECUTIVE PARK
NEWTON, MA 02462
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments396294
Cash and cash equivalents396294
Other undisclosed current assets232
Total current assets:426496
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment010
Other noncurrent assets000
Total noncurrent assets:110
TOTAL ASSETS:436596
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities764
Accounts payable422
Accrued liabilities342
Debt4 4
Total current liabilities:1068
Noncurrent Liabilities
Long-term debt and lease obligation7106
Long-term debt, excluding current maturities7106
Operating lease, liability0
Liabilities, other than long-term debt 00
Other liabilities 00
Total noncurrent liabilities:7106
Total liabilities:181613
Stockholders' equity
Stockholders' equity attributable to parent254983
Common stock000
Additional paid in capital179167165
Accumulated deficit(154)(118)(82)
Total stockholders' equity:254983
TOTAL LIABILITIES AND EQUITY:436596

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses(46)(36)(21)
Operating loss:(46)(36)(21)
Nonoperating income (expense)0(0)(1)
Investment income, nonoperating01(0)
Other nonoperating expense(0)(0)(0)
Interest and debt expense (1) 
Loss before gain (loss) on sale of properties:(46)(36)(22)
Other undisclosed net income 1 
Net loss attributable to parent:(46)(36)(22)
Preferred stock dividends and other adjustments  (0)
Net loss available to common stockholders, diluted:(46)(36)(22)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(46)(36)(22)
Comprehensive loss, net of tax, attributable to parent:(46)(36)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: